GLP-1s and Blood Pressure: How These Medications Affect Your Numbers

What the Clinical Trials Show

Large-scale trials have measured blood pressure changes in thousands of patients on GLP-1 medications. The reductions are modest but consistent.

STEP Trials — Semaglutide (Ozempic, Wegovy)

The STEP program tested semaglutide 2.4 mg for weight management across five trials. In STEP 1, participants on semaglutide had an average systolic blood pressure reduction of 5.4 mmHg compared to 1.1 mmHg with placebo. STEP 2 showed a 4.6 mmHg reduction in the semaglutide group versus 1.9 mmHg with placebo. STEP 3 combined semaglutide with intensive behavioral therapy and found a 6.7 mmHg systolic reduction. STEP 5, which extended treatment to 2 years, showed sustained reductions of roughly 4-5 mmHg.

Diastolic blood pressure (the bottom number) also dropped, typically by 1 to 3 mmHg across the STEP trials.

SURPASS Trials — Tirzepatide (Mounjaro, Zepbound)

The SURPASS program tested tirzepatide at 5 mg, 10 mg, and 15 mg doses. In SURPASS 1 through 5, systolic blood pressure reductions ranged from 3.5 to 8.4 mmHg depending on the dose and study population. The 15 mg dose consistently produced the largest reductions. SURPASS 2, which compared tirzepatide to semaglutide 1 mg, found that tirzepatide 15 mg lowered systolic BP by approximately 7 mmHg compared to 4 mmHg with semaglutide 1 mg.

The SURPASS-4 trial, which focused on cardiovascular risk, reported systolic reductions of 5.6 to 7.4 mmHg across tirzepatide doses.

LEADER Trial — Liraglutide (Victoza, Saxenda)

The LEADER trial followed over 9,000 participants with type 2 diabetes for a median of 3.8 years. Liraglutide 1.8 mg reduced systolic blood pressure by an average of 2.3 mmHg compared to placebo. This reduction was observed within the first 12 weeks and remained stable throughout the trial. LEADER also showed a 13% reduction in cardiovascular death, though blood pressure reduction was only one of several contributing factors.

Dose-Response: Does More GLP-1 Mean More BP Reduction?

The data suggests a dose-dependent relationship, but it is not linear.

In the SURPASS trials, higher tirzepatide doses produced greater blood pressure reductions. The 5 mg dose lowered systolic BP by about 3.5-5 mmHg, while the 15 mg dose lowered it by 6-8.4 mmHg.

With semaglutide, the STEP trials at 2.4 mg showed larger BP reductions than earlier trials at lower doses (0.5 mg and 1 mg), which typically showed 1-2 mmHg reductions. However, some of this dose-response effect is likely driven by greater weight loss at higher doses rather than a direct drug effect alone.

The contribution of weight loss versus direct GLP-1 action remains debated. Research suggests that roughly 50-70% of the blood pressure reduction is mediated through weight loss. The remaining 30-50% appears to be a direct effect of GLP-1 receptor activation on the cardiovascular system and kidneys.

How Quickly Blood Pressure Changes Appear

Blood pressure reductions do not take months to show up. In the LEADER trial, measurable systolic BP differences between liraglutide and placebo groups appeared by week 4. The STEP trials reported early BP changes within the first 8 weeks of treatment, often before significant weight loss had occurred.

This early onset supports the idea that some of the blood pressure effect is independent of weight loss. Direct mechanisms like sodium excretion and blood vessel dilation may act within days to weeks.

Most of the blood pressure reduction is typically reached by 16 to 20 weeks. After that, readings tend to stabilize rather than continue declining.

The Mechanisms: Why GLP-1s Lower Blood Pressure

1. Weight Loss

Excess weight increases blood volume and puts more mechanical stress on blood vessel walls. Losing weight reduces that strain. Weight loss is the largest single contributor to blood pressure reduction on GLP-1 medications. In the STEP 1 trial, participants who lost more weight tended to show larger BP reductions.

2. Sodium Excretion and Kidney Effects

GLP-1 receptors are expressed in the kidney, specifically in the proximal tubule and the juxtaglomerular apparatus. When GLP-1 binds to these receptors, it appears to promote natriuresis — the excretion of sodium in urine.

A 2019 study in Hypertension found that GLP-1 receptor agonists increased urinary sodium excretion by 30-40% in animal models. Human studies have confirmed increased sodium output in patients on liraglutide and semaglutide. Less sodium retention means less fluid volume in the blood vessels, which directly lowers blood pressure.

GLP-1 receptor activation in the kidney also appears to suppress the renin-angiotensin-aldosterone system (RAAS) at the level of renin release. This is the same system targeted by ACE inhibitors and ARBs, which is why combining GLP-1s with those drugs can produce additive blood pressure reductions.

3. Endothelial Function

The endothelium is the inner lining of blood vessels. When it functions well, vessels dilate and constrict appropriately. When it functions poorly, vessels stay constricted, and blood pressure rises.

Research suggests GLP-1s improve endothelial function. A 2018 meta-analysis in Diabetes Care found that GLP-1 receptor agonists significantly improved flow-mediated dilation, a standard measure of endothelial health. The improvement was observed within 12 to 16 weeks of treatment. Better endothelial function means blood vessels can relax more effectively, which contributes to lower blood pressure.

GLP-1 receptor activation increases nitric oxide production in endothelial cells. Nitric oxide is a signaling molecule that tells blood vessels to relax. GLP-1s also appear to reduce oxidative stress in the endothelium, which preserves nitric oxide availability.

4. Reduced Inflammation

Chronic inflammation contributes to high blood pressure by promoting arterial stiffness and endothelial dysfunction. GLP-1s reduce markers of systemic inflammation, including C-reactive protein (CRP) and several pro-inflammatory cytokines. See our heart health article for more on GLP-1s and cardiovascular inflammation.

5. Better Blood Sugar Control

High blood sugar damages blood vessels over time through advanced glycation end-products (AGEs), which stiffen vessel walls. GLP-1s improve blood sugar control, which may slow this damage. See our cholesterol article for related effects on lipid profiles.

Orthostatic Hypotension: The Risk of Dropping Too Low

Orthostatic hypotension is a blood pressure drop when you stand up from sitting or lying down. Symptoms include dizziness, lightheadedness, and sometimes fainting.

GLP-1 medications alone rarely cause orthostatic hypotension. The risk increases substantially when GLP-1s are combined with antihypertensive medications. This is especially true for:

• People over 65 — age-related baroreceptor changes already increase orthostatic risk
• People on multiple blood pressure medications — additive effects increase the chance of over-treatment
• People who have lost significant weight quickly — blood volume adjustments may lag behind weight loss
• People with diabetes and autonomic neuropathy — impaired blood pressure regulation makes overcorrection more likely

If you take blood pressure medication and start a GLP-1, stand up slowly from seated or lying positions. Sit back down immediately if you feel dizzy. Check your blood pressure in both seated and standing positions.

Drug Interactions With Common Antihypertensives

ACE Inhibitors (lisinopril, enalapril, ramipril)

GLP-1s and ACE inhibitors both affect the renin-angiotensin system through different pathways. The combination may produce additive blood pressure reductions. Monitor for dizziness and lightheadedness, especially in the first 8 weeks of GLP-1 treatment. Your doctor may reduce the ACE inhibitor dose if your readings drop below target.

ARBs (losartan, valsartan, olmesartan)

Similar to ACE inhibitors, ARBs combined with GLP-1s may lower blood pressure more than either drug alone. The interaction is pharmacodynamic (additive effect), not pharmacokinetic (no change in drug levels). Monitoring recommendations are the same as for ACE inhibitors.

Diuretics (hydrochlorothiazide, chlorthalidone, furosemide)

This combination requires close attention. GLP-1s promote sodium and water excretion. Diuretics also promote sodium and water excretion. Together, they may cause excessive fluid loss, low blood pressure, and electrolyte imbalances (particularly low potassium and low sodium). If you take a diuretic and start a GLP-1, your doctor may reduce the diuretic dose. Electrolyte packets can help maintain mineral balance if your doctor approves them.

Beta-Blockers (metoprolol, atenolol, carvedilol)

Beta-blockers lower heart rate and blood pressure. GLP-1s also tend to modestly reduce heart rate (by 2-6 beats per minute in clinical trials). The combined effect on heart rate and blood pressure may be additive. Watch for fatigue, slow heart rate, and dizziness. Beta-blockers can also mask some symptoms of low blood sugar, which is relevant if you have diabetes.

Calcium Channel Blockers (amlodipine, nifedipine)

Limited specific interaction data exists for GLP-1s and calcium channel blockers. The additive blood pressure effect is possible but appears less pronounced than with diuretics or RAAS inhibitors. Standard monitoring is sufficient.

Monitoring Protocol: How and When to Check

How Often to Check

• First 3 months of GLP-1 treatment: Check blood pressure at least twice a week, ideally at the same time of day
• Months 3-6: Check once a week if readings are stable
• After 6 months: Check 2-4 times per month if blood pressure is well-controlled

What Readings to Flag

• Systolic below 100 mmHg — contact your doctor, especially if you feel dizzy
• Systolic below 90 mmHg — seek medical attention promptly
• Standing systolic more than 20 mmHg below seated systolic — this indicates orthostatic hypotension
• Any reading significantly below your usual range — even if the number itself is not dangerously low, a sudden drop from your baseline matters

Ambulatory Blood Pressure Monitoring vs. Office Readings

Office blood pressure readings have limitations. White coat hypertension (elevated readings only in the doctor's office) and masked hypertension (normal in the office but elevated elsewhere) affect up to 30% of patients.

Ambulatory blood pressure monitoring (ABPM) uses a device that takes readings every 20-30 minutes over a 24-hour period. ABPM provides a more complete picture of your blood pressure patterns, including nighttime readings.

Research suggests GLP-1 medications may have a greater effect on nighttime blood pressure than daytime readings. A 2020 study in the Journal of Hypertension found that liraglutide reduced nocturnal systolic BP by 5.2 mmHg versus 2.1 mmHg during the daytime. Nighttime blood pressure is increasingly recognized as a stronger predictor of cardiovascular events than daytime readings.

If your doctor suspects your blood pressure is not well-characterized by office readings alone, ask about ABPM. A home blood pressure monitor validated by the American Medical Association is a practical alternative for regular tracking.

When Your Doctor Might Reduce Your Blood Pressure Medication

Dose reduction may be appropriate when:

• Your systolic readings are consistently below 110 mmHg on your current regimen
• You experience orthostatic symptoms (dizziness when standing)
• You have lost more than 10% of your body weight on the GLP-1
• Your blood pressure has been stable at a lower level for at least 4 weeks

Dose reduction is generally not appropriate when:

• Your blood pressure is still above your target range
• You have a history of heart attack, stroke, or heart failure — maintaining tight control is critical
• The GLP-1 effect is new and may not be sustained yet (wait at least 8-12 weeks)
• You have chronic kidney disease — blood pressure control protects kidney function

See our kidney health article for more on how blood pressure and kidney function interact.

Lifestyle Still Matters

GLP-1s help, but they don't replace healthy habits:

• Reduce sodium: Aim for less than 2,300mg per day (ideally 1,500mg if you have high blood pressure)
• Exercise: 150 minutes per week of moderate activity
• Limit alcohol: No more than 1 drink per day for women, 2 for men
• Manage stress: Chronic stress raises blood pressure
• Don't smoke: Smoking damages blood vessels and raises blood pressure

For people just starting GLP-1 treatment, see our starter guide for a complete overview of what to expect.

When to See Your Doctor

• Your blood pressure readings are consistently lower than usual after starting a GLP-1
• You're experiencing dizziness, lightheadedness, or fainting
• You want to discuss adjusting your blood pressure medications
• Your blood pressure isn't improving despite lifestyle changes and GLP-1 treatment
• Your seated-to-standing blood pressure drops by more than 20 mmHg

The Bottom Line

GLP-1 medications lower blood pressure through multiple mechanisms: weight loss, sodium excretion via kidney GLP-1 receptors, improved endothelial function, reduced inflammation, and better blood sugar control. Clinical trial data shows reductions of 2-8 mmHg systolic depending on the drug and dose. These changes can appear within the first 2-4 weeks.

The main risk is additive blood pressure reduction when GLP-1s are combined with antihypertensive medications, particularly diuretics and RAAS inhibitors. Orthostatic hypotension is the most common consequence.

Your action items:

1. Monitor your blood pressure regularly after starting a GLP-1 — at least twice weekly for the first 3 months
2. Tell your doctor if your readings are consistently lower than your baseline
3. Don't adjust your blood pressure medications without medical guidance
4. Check both seated and standing blood pressure if you feel dizzy
5. Consider ambulatory monitoring if office readings don't match how you feel
6. Watch for signs of orthostatic hypotension, especially if you take diuretics or ACE inhibitors/ARBs

Even a small reduction in blood pressure adds up over time. A 5 mmHg systolic reduction is associated with approximately 10% lower risk of major cardiovascular events.

This article is for informational purposes only and does not replace medical advice. Always talk to your healthcare provider about blood pressure management and medication changes.

Found this helpful? Share it with someone managing high blood pressure who might benefit from a GLP-1.